Jobs
-
Inhaled drug developer Senzer has announced major changes to its management “aimed at bolstering its commercialization strategy for COVID-19 and cannabinoid treatments.” In May 2020, Senzer announced that it was developing two inhaled anti-virals delivered… Read more . . .
-
AstraZeneca said that complete results from the Phase 3 ETHOS trial of its Breztri Aerosphere (PT010) budesonide/glycopyrronium/formoterol fumarate MDI demonstrated that the triple combination reduced moderate or severe COPD exacerbations by 24% compared to glycopyrronium/formoterol… Read more . . .
-
VistaGen Therapeutics has announced that it signed a deal giving EverInsight Therapeutics development and commercialization rights to Vistagen’s PH94B aloradine nasal spray for anxiety disorders in China, South Korea, and a number of other Asian countries.… Read more . . .
-
Gilead Sciences Chairman and CEO Daniel O’Day has announced that the company has received FDA approval for a Phase 1 trial of inhaled remdesivir and will initiate the study within a week. Trials of the… Read more . . .
-
Vaccine developer Intravacc has published data from a preclinical study of an intranasal whooping cough vaccine demonstrating strong immune responses in mice. The intranasal vaccine also prevented colonization of the lung, trachea, and nose by… Read more . . .
-
Inhalation Sciences (ISAB) has announced that a “noted global pharma company” has placed an order worth €75,000 for a contract research project utilizing ISAB’s DissolvIt system. The DissolvIt module is used to simulate dissolution and… Read more . . .
-
The FDA has approved Evoke Pharma’s Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, the company said. Evoke originally submitted an NDA for Gimoti in in June 2018 and acknowledged receipt of a complete response… Read more . . .
-
DPI developer TFF Pharmaceuticals said that the FDA has granted orphan drug designation to its dry powder tacrolimus for the prevention of lung transplant rejection. The company also said that it plans to initiate a… Read more . . .
-
North Carolina-based Renovion said that it has raised $8.1 million in a Series A financing round for development of its ARINA-1 nebulized glutathione/bicarbonate/ascorbic acid formulation for the treatment of chronic lung diseases. ARINA-1, which is… Read more . . .
-
Tonix Pharmaceuticals has announced that it will acquire assets from Trigemina, Inc that include intranasal oxytocin for the treatment of migraine headaches. Trigemina had licensed the nasal spray, now called TNX-1900, from Stanford University, and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland